Island Pharmaceuticals (ASX:ILA) Insider Christopher Ntoumenopoulos Purchases 844,568 Shares of Stock

Island Pharmaceuticals Limited (ASX:ILA) insider Christopher Ntoumenopoulos acquired 844,568 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was bought at an average price of A$0.07 per share, with a total value of A$59,119.76.

Island Pharmaceuticals Stock Performance

The firm has a market capitalization of $25.60 million, a P/E ratio of -4.85 and a beta of 0.40. The company has a quick ratio of 8.28, a current ratio of 2.45 and a debt-to-equity ratio of 27.78.

About Island Pharmaceuticals

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing various molecules that could be searched for drug re-purposing and pipeline development.